|

cemiplimab+fianlimab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Grupo Español Multidisciplinar de Melanoma1

Indications

  • Melanoma and Brain Metastases1
  • Melanoma BRAF V600E/K Mutated1
  • Cancer1

Other1 trial

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.